NASDAQ:PTPI Petros Pharmaceuticals 8/14/2024 Earnings Report $0.07 -0.06 (-46.45%) Closing price 05/21/2025 04:00 PM EasternExtended Trading$0.04 -0.03 (-41.87%) As of 05/21/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Earnings History Petros Pharmaceuticals EPS ResultsActual EPS-$9.25Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/APetros Pharmaceuticals Revenue ResultsActual Revenue$1.42 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/APetros Pharmaceuticals Announcement DetailsQuarterDate8/14/2024TimeN/AConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Petros Pharmaceuticals Earnings HeadlinesPetros Pharmaceuticals, Inc.: Petros Pharmaceuticals Partners with Innolitics, a Leading Software-as-a-Medical-Device DeveloperMay 20 at 10:54 PM | finanznachrichten.dePetros Pharmaceuticals, Inc.: Petros Pharmaceuticals to Partner with Renowned Big Data Provider to Enable Rx-to-OTC Switch Across Multiple IndicationsMarch 20, 2025 | finanznachrichten.deJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are already using to their advantage… It allows them to treat this new asset like actual cash.May 22, 2025 | Premier Gold Co (Ad)Petros Pharmaceuticals enters collaboration with big data, analytics firmMarch 20, 2025 | msn.comPetros Pharmaceuticals, Inc.: Petros Pharmaceuticals' Proprietary Technology Demonstrates Positive Data in Pivotal StudyFebruary 27, 2025 | finanznachrichten.dePetros Pharmaceuticals announces top-line results of expanded App Comp studyFebruary 25, 2025 | markets.businessinsider.comSee More Petros Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Petros Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Petros Pharmaceuticals and other key companies, straight to your email. Email Address About Petros PharmaceuticalsPetros Pharmaceuticals (NASDAQ:PTPI), a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, penile injections, PreBoost, VenoSeal, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.View Petros Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Alibaba's Earnings Just Changed Everything for the StockCisco Stock Eyes New Highs in 2025 on AI, Earnings, UpgradesSymbotic Gets Big Earnings Lift: Is the Stock Investable Again?D-Wave Pushes Back on Short Seller Case With Strong EarningsAppLovin Surges on Earnings: What's Next for This Tech Standout?Can Shopify Stock Make a Comeback After an Earnings Sell-Off?Rocket Lab: Earnings Miss But Neutron Momentum Holds Upcoming Earnings PDD (5/27/2025)AutoZone (5/27/2025)Bank of Nova Scotia (5/27/2025)NVIDIA (5/28/2025)Synopsys (5/28/2025)Bank of Montreal (5/28/2025)Salesforce (5/28/2025)Costco Wholesale (5/29/2025)Marvell Technology (5/29/2025)Canadian Imperial Bank of Commerce (5/29/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
